Xspray Pharma’s Rights Issue Oversubscribed and Over-Allotment Expanded

Xspray Pharma AB ( (SE:XSPRAY) ) has issued an update.

Xspray Pharma has strengthened the financing of its ongoing SEK 83 million rights issue by securing additional subscription undertakings of SEK 44 million from new investors, plus a SEK 2 million subscription intention from an existing shareholder. These commitments mean the rights issue is now covered to approximately 110 percent, with all undertakings made on the same terms as other investors and without compensation.

Due to high investor interest, including commitments from Life Science Invest Fund I and a Swiss family office, Xspray’s board has increased the planned over-allotment issue from SEK 20 million to SEK 30 million to accommodate potential oversubscription. The moves enhance the company’s capital-raising capacity at a subscription price of SEK 20 per share, potentially bolstering its financial position and signaling solid market support ahead of the April subscription period.

The most recent analyst rating on (SE:XSPRAY) stock is a Sell with a SEK26.00 price target. To see the full list of analyst forecasts on Xspray Pharma AB stock, see the SE:XSPRAY Stock Forecast page.

More about Xspray Pharma AB

Xspray Pharma AB is a Sweden-based pharmaceutical company focused on developing improved versions of existing oncology drugs, leveraging formulation technologies to enhance bioavailability and patient outcomes. The company targets the life sciences and healthcare investment community, attracting specialized funds and family offices interested in innovative cancer therapeutics.

Average Trading Volume: 47,915

Technical Sentiment Signal: Sell

Current Market Cap: SEK1.15B

See more data about XSPRAY stock on TipRanks’ Stock Analysis page.